Prior authorization for ACCUZYME and PANAFIL is not required.
ACCUZYME Ointment, Papain, Urea, 30 gram tube (NDC# 00064-1000-01) and PANAFIL Ointment, Papain, Urea, Chlorophyllin Copper Complex Sodium, 30 gram tube (NDC# 00064-3410-30) are readily available at pharmacies and drug wholesalers in California and nationwide.
The sole source status for ACCUZYME Ointment became effective December 2003, and sole source status for PANAFIL Ointment took effect March 2004.
PANAFIL is a healing, debriding and deodorizing ointment indicated for treatment of acute and chronic lesions such as varicose, diabetic and decubitus ulcers, burns, postoperative wounds, pilonidal cyst wounds, carbuncles and miscellaneous traumatic or infected wounds.
According to HEALTHPOINT, the suit against Stratus was instituted when the company learned that patients were being prescribed Accuzyme and Panafil, yet Kovia and Ziox were substituted without a determination that the substituted products were pharmaceutically equivalent, therapeutically equivalent or bioequivalent.
HEALTHPOINT's victory shows that Stratus's use of terms and phrases like "generic," "generic alternative," "branded generic," "bioequivalent," or "equivalent" wrongly suggested that Kovia is interchangeable with Accuzyme and that Ziox is interchangeable with Panafil.
The court said that there had been no evidence submitted to show that there is a current drug product that has demonstrated pharmaceutical equivalence, therapeutic equivalence, bioequivalence, or generic equivalence to Accuzyme or Panafil.
Upon the acquisition of PANAFIL
from Integra Life Sciences in 1998, HEALTHPOINT began emphasizing in its marketing approach the healing properties the product's chlorophyllin copper complex sodium provides to granulating wounds in conjunction with its proteolytic enzyme.
Sturza shows complete ignorance of the products he himself cites as competition by referring to Panafil
as a wound healing agent.